Topics:

Multiple Myeloma

Multiple Myeloma

Autologous stem cell transplant led to significantly longer overall survival than non-transplant strategies in a cohort of elderly patients with multiple myeloma.

The addition of elotuzumab to lenalidomide and dexamethasone improved progression-free survival and overall response rate in relapsed multiple myeloma patients.

Treatment with carfilzomib and dexamethasone doubled the PFS in relapsed multiple myeloma patients compared with treatment with bortezomib and dexamethasone.

Multiple myeloma patients had better overall survival if they had prior knowledge of having monoclonal gammopathy of undetermined significance.

The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.

The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.

A scoring system that measured frailty in elderly patients with multiple myeloma was able to accurately predict mortality and risk of toxicity.

Pages

Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.